Skip to main content

Leukemia News (Page 2)

Related terms: Cancer, Leukemia

Position Statement Developed for Managing Blood Cancers in Pregnancy

WEDNESDAY, Jan. 8, 2025 – In a new position statement published online Jan. 3 in The Lancet Haematology, guidelines are presented for the management of acute leukemia and aggressive lymphomas in...

Neurocognitive Battery Feasible in 3-Year-Olds During Leukemia Treatment

WEDNESDAY, Dec. 18, 2024 – A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according to a study published online Dec. 9 in Pediatric...

COVID-19 Mortality Higher for Leukemia, Myelodysplastic Syndrome Patients

THURSDAY, Nov. 21, 2024 – The risk for COVID-19 hospitalization is low in adults with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), but these individuals have a high mortality...

FDA Approves Revuforj (revumenib) for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ – Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) as the first and...

Protracted Radiation Exposure Linked to Hematologic Cancer Mortality

THURSDAY, Oct. 24, 2024 – Protracted low-dose exposure to ionizing radiation among radiation-monitored workers is associated with mortality due to some hematologic malignancies, according to a study...

Radon Exposure Tied to Higher Risk for Childhood Leukemia

WEDNESDAY, Oct. 16, 2024 – Exposure to radon levels, even below current recommended levels, heightens the risk for childhood leukemia, according to a study published in the December 2024 issue...

Overall Survival Improving for Umbilical Cord Blood Transplant

MONDAY, Oct. 7, 2024 – For umbilical cord blood transplant (UCBT), overall survival has improved over time, according to a study published in the October issue of Transplantation and Cellular...

Fear of Cancer Recurrence Common Decades After Surviving Childhood Cancer

FRIDAY, Oct. 4, 2024 – A third of childhood cancer survivors experience fear of recurrence even decades later, according to a study published online Oct. 3 in JAMA Network Open. Alex Pizzo, from ...

Even Low Levels of Radon May Raise Children's Risk for Leukemia

FRIDAY, Oct. 4, 2024 — Growing up in a city with pockets of high radon levels, Matthew Bozigar wondered whether the radioactive gas might have anything to do with the high rates of cancer he saw a...

Black, White Cancer Patients Now Benefit Equally From Cord Blood Therapy

TUESDAY, Oct. 1, 2024 – Blood cancer patients of all races who receive cord blood transplants are now living longer. The finding, reported by a team led by oncologist Dr. Karen Ballen, of UVA...

Blood Cancers: What You Need to Know

SATURDAY, Sept. 28, 2024 – Blood cancer is not a diagnosis anyone wants to receive, but understanding the different types of this disease and how best to catch them early is essential, one expert...

Non-Hispanic Black Patients Have Disparities in HCT Use for Hematologic Cancers

THURSDAY, Sept. 26, 2024 – Non-Hispanic Black patients in the United States appear to have persistent disparities in terms of hematopoietic cell transplantation (HCT) for various hematologic...

Measurable Residual Disease Results After Consolidation Therapy Predictive of Relapse in Pediatric Leukemia

TUESDAY, Sept. 24, 2024 – For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation (EOC) can be used to predict the need for...

FDA Medwatch Alert: Drug Safety Communication: Copiktra (duvelisib) - FDA Warns about Possible Increased Risk of Death and Serious Side Effects

ISSUE: The FDA is warning that results from a clinical trial show a possible increased risk of death with Copiktra (duvelisib) compared to another medicine to treat a chronic blood cancer called...

FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia

21 November 2019 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or s...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hairy Cell Leukemia, Blood Disorders

Related drug support groups

prednisone, triamcinolone, dexamethasone